ALUPENT
LOE ApproachingNDAORALSYRUP
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral syrup small-molecule bronchodilator approved in 1975 by Boehringer Ingelheim. The drug's specific mechanism of action and therapeutic indications are not currently documented in available data. This legacy product represents a mature asset in a crowded respiratory market.
LOE Approaching
As LOE approaches, the brand team is likely in defensive mode with minimal headcount expansion; roles focus on retention and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALUPENT offers limited career growth as the product approaches end-of-life; roles are focused on defending market share and managing the transition to generics. This assignment is typically suited to early-career professionals seeking compliance and regulatory experience or those managing legacy portfolios.
Brand ManagerMedical Science Liaison
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.